Search
Oteracil
go.drugbank.com/drugs/DB03209ApprovedInvestigationalOteracil is an adjunct to antineoplastic therapy, used to reduce the toxic side effects associated with chemotherapy. … By mimicking a class of compounds called "pyrimidines" that are essential components of RNA and DNA, 5-FU is able to insert itself into strands of DNA and RNA, thereby halting the replication process necessary
Mixtures: TS-ONE CAPSULE 20, TS-ONE CAPSULE 20Ravulizumab
go.drugbank.com/drugs/DB11580ApprovedInvestigational[L39690] Ravulizumab was engineered from [eculizumab], another complement inhibitor, to increase the duration of action and reduce the frequency of drug administration. … [A244465] It was later approved by the European Commission on July 2, 2019, for the same indications.[L39710] Ravulizumab is also used to treat myasthenia gravis.
Artemether
go.drugbank.com/drugs/DB06697ApprovedInvestigational</i> and may be used to treat infections caused by <i>P. falciparum</i> and unidentified <i>Plasmodium</i> species, including infections acquired in chloroquine-resistant areas. … Artemether is an antimalarial agent used to treat acute uncomplicated malaria. It is administered in combination with lumefantrine for improved efficacy.
Dibotermin alfa
go.drugbank.com/drugs/DB11639ApprovedInvestigationalDibotermin alfa is a recombinant human bone morphogenetic protein-2 (rhBMP-2) derived from a recombinant Chinese Hamster Ovary (CHO) cell line [FDA Label]. … Dibotermin alfa was approved by the EMA in 2002 as Inductos for implantation matrix. In 2004, it was approved by the FDA and is marketed as Infuse.
Danaparoid
go.drugbank.com/drugs/DB06754ApprovedWithdrawnWhile it was initially approved by the FDA as Orgaran™, danaparoid was withdrawn by Organon International on August 14, 2002, due to a shortage in drug substance by the manufacturer. … It is chemically distinct from heparin by containing different protein binding properties, thus has lower cross-reactivity in heparin-intolerant patients.
Odesivimab
go.drugbank.com/drugs/DB15900ApprovedInvestigational[A221825] Immune therapy using monoclonal antibodies (mAbs) is becoming an increasingly attractive therapeutic method to combat infectious diseases due to its rapid development, low toxicity, and high … INMAZEB™ is produced by Regeneron Pharmaceuticals and was granted FDA approval on October 14, 2020.[L17320]
Profenamine
go.drugbank.com/drugs/DB00392ApprovedProfenamine (also known as ethopropazine) is a medication derived from phenothiazine. It is primarily used as an antidyskinetic to treat Parkinsonism.
Synonyms: N,N-diethyl-1-(10H-phenothiazin-10-yl)-2-propanamine, N,N-diethyl-α-methyl-10H-phenothiazine-10-ethanamineBimekizumab
go.drugbank.com/drugs/DB12917ApprovedInvestigationalof moderate-to-severe psoriasis,[A244450,A244455] likely owing to its dual inhibition of both IL-17A and IL-17F. … [L39665,L39680] It is the first IL-17 inhibitor to target both IL-17A and IL-17F.
Molnupiravir
go.drugbank.com/drugs/DB15661Investigational[A193014] A [remdesivir] resistant mutant mouse hepatitis virus has also been shown to have increased sensitivity to N4-hydroxycytidine. … [A193014] Molnupiravir was granted approval by the UK's Medicines and Health products Regulatory Agency (MHRA) on 4 November 2021 to prevent severe outcomes such as hospitalization and death due to
Rotigotine
go.drugbank.com/drugs/DB05271ApprovedInvestigationalRotigotine was developed by Aderis Pharmaceuticals. In 1998 Aderis licensed worldwide development and commercialization rights to Schwarz Pharma of Germany. … It was approved by the European Medicines Agency in 2006 and by the FDA in 2007.
Categories: Serotonergic Drugs Shown to Increase Risk of Serotonin Syndrome